Hitachi Chemical Co. America, Ltd. (San Jose, California), a subsidiary of Hitachi Chemical (Tokyo) has completed its purchase of the 80.1% remaining membership interest in PCT Cell Therapy Services (PCT, New Jersey) from Caladrius Biosciences.
Following the acquisition, PCT has become an independent business unit dedicated to cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.
Hitachi Chemical will leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network and other resources to expand and strengthen services in the United States and add services in Japan, Europe, and other regions. In addition, PCT will be able to expand manufacturing capacity, capabilities, and service offerings.
“The acquisition of PCT marks an important milestone in the expansion of Hitachi Chemical’s regenerative medicine-related businesses,” says Hisashi Maruyama, CEO, Hitachi Chemical.
By Kartik Kohli
Source: Chemical Week
INEOS, Europe’s biggest operator of electrolysis needed to produce clean, low carbon hydrogen, has doubled down on its €2 billion investment in green hydrogen with the launch of a hydrogen advocacy campaign. The campaign kicked off with the publication of a powerful editorial in the Sunday Telegraph on the hydrogen economy written by Sir Jim Ratcliffe, INEOS’s founder and chairman.
Vertellus, a manufacturer of specialty products for consumer goods, food & agriculture, healthcare, and industrial markets, today announced the completion of its acquisition of IM Chemicals. With the addition of IM Chemicals, Vertellus expands its specialty ingredients portfolio into new markets and bolsters its manufacturing capabilities in Europe.
A new collaboration between scientists, engineers, industry and farming experts hopes to demonstrate how clever technology can reduce the powerful greenhouse gases released by livestock to help agriculture reach carbon emissions targets.
